Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine (Serum Institute of India)
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This acellular pertussis vaccine is being developed by the Serum Institute of India (SIIPL) as part of a diphtheria, tetanus, and acellular pertussis (DTaP) combination vaccine. The vaccine contains purified antigenic components of *Bordetella pertussis*, specifically Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), and Pertactin, combined with diphtheria and tetanus toxoids. Formulated as a suspension adsorbed on an aluminum adjuvant, its mechanism of action involves eliciting protective antibody responses against these three pathogens. While the DTaP formulation was initially noted in preclinical development and toxicology studies at the NIBSC, SIIPL has since progressed a Tdap booster formulation into Phase II/III clinical trials in India and Germany, demonstrating non-inferior immunogenicity and safety compared to licensed vaccines.
- Other names
- DTaP VaccineTdap vaccineDTP combination
02
Targets
FHA (Filamentous hemagglutinin)PRN (Pertactin)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine (Serum Institute of India).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine (Serum Institute of India).